SCHEDULE: Rosalind Advisors Discloses 9.9% Stake in Regentis Biomaterials

Rosalind Advisors Inc. and its affiliated entities have reported beneficial ownership of 9.9% of Regentis Biomaterials Ltd.'s common shares, primarily through warrants and existing shares.

Summary

• Rosalind Advisors Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon have collectively reported beneficial ownership of 1,428,570 shares of Regentis Biomaterials Ltd. common stock.
• This represents approximately 9.9% of the issuer's outstanding common shares as of July 8, 2026.
• The reported shares include 701,685 directly held common shares and 726,885 shares issuable upon exercise of warrants.
• Rosalind Advisors Inc. acts as the investment advisor to Rosalind Master Fund L.P.
• Steven Salamon is the portfolio manager for Rosalind Advisors Inc., and Gilad Aharon is also a portfolio manager and member of Rosalind Advisors Inc.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to the disclosure of significant beneficial ownership which can indicate investor confidence, but without immediate actionable financial performance data.

Positives

• Significant beneficial ownership disclosed by Rosalind Advisors and related parties, indicating substantial investor interest.
• The reporting entities collectively hold a notable 9.9% stake in Regentis Biomaterials Ltd.

Negatives

• The filing does not provide current financial performance data or recent operational updates for Regentis Biomaterials Ltd.
• The reported beneficial ownership is subject to the exercise of warrants, meaning the actual current ownership of common stock is lower than the potential ownership.

Risks

• The actual number of common shares beneficially owned by the reporting persons is less than indicated due to 'blockers' associated with warrant exercise, which are not detailed.
• The filing does not provide specific details on the terms or expiration of the warrants, which could impact future ownership levels.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Regentis Biomaterials Ltd.'s future performance. It solely focuses on ownership disclosure.

Management Comments

• Rosalind Advisors Inc. disclaims beneficial ownership of the shares held by Rosalind Master Fund L.P.
• Steven Salamon disclaims beneficial ownership of the shares held by Rosalind Master Fund L.P.
• Mike McDonald, Director of Rosalind (Cayman) Ltd. (as General Partner to Rosalind Master Fund), signed on behalf of Rosalind Master Fund L.P.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes. The disclosure by Rosalind Advisors and its affiliates suggests a significant, but likely non-controlling, interest in Regentis Biomaterials, a company operating in the biomaterials sector.

Comparison to Industry Standards

• Industry standard for Schedule 13G filings is to report beneficial ownership exceeding 5% of a class of securities.
• The 9.9% stake reported by Rosalind Advisors is a common threshold for significant institutional investors.
• Companies in the biomaterials sector often attract strategic or financial investors looking for growth opportunities, and this filing aligns with that trend.

Related Party Transactions

• Rosalind Advisors Inc. acts as the investment advisor to Rosalind Master Fund L.P.
• Steven Salamon is the portfolio manager of Rosalind Advisors Inc., which advises Rosalind Master Fund L.P.
• Gilad Aharon is a portfolio manager and member of Rosalind Advisors Inc., which advises Rosalind Master Fund L.P.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by an investment advisor and fund may signal increased institutional interest, potentially influencing share price and corporate strategy.
• Management: The increased ownership stake may lead to closer scrutiny or engagement from the reporting entities.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• Monitor future filings from Rosalind Advisors and Regentis Biomaterials for any changes in ownership or strategic developments.
• Observe potential future warrant exercises by Rosalind Master Fund L.P.

Key Dates

Keywords

Regentis Biomaterials, Rosalind Advisors, Rosalind Master Fund, Schedule 13G, Beneficial Ownership, Warrants, Investment Advisor, Portfolio Manager